ArticleThe Journal of clinical endocrinology and metabolism2022
Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation.
Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- Associations of breast DNA methylation-based measures of biological ageing with obesity-related breast cancer risk markers.Epigenetics · 2026Article
- Cancer risk and mortality assessment in the overweight population: evaluation of single and integrated models based on inflammatory markers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease.Breast cancer research and treatment · 2026Article
- Cancer-associated adipocytes: metabolic reprogramming, crosstalk and therapeutic implications in tumor progression.Signal transduction and targeted therapy · 2026Review
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Review
- Association of METS-IR with breast cancer risk: a large-scale retrospective cohort study of Korean women.BMC public health · 2026Article
- Risk Stratification of Fibroepithelial Breast Lesions: Clinical and Ultrasound Features Associated with Fibroadenoma and Phyllodes Tumors.Annals of surgical oncology · 2026Article
- Targeting metabolic dysregulation in postmenopausal breast cancer: Synergistic effects of nutrition-based interventions and exercise on molecular and cellular pathways.Cancer cell international · 2026Review
- Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox.Metabolites · 2026Review
- The Role of Angiogenesis in Breast Cancer and Obesity: Unravelling the Connection.International journal of breast cancer · 2026Review
- VEGF-Leptin Crosstalk in Breast and Ovarian Cancer: Drivers of Angiogenesis and Progression.Cancer management and research · 2026Review
- The Current and Future Burden of Metabolic Dysfunction-related Cancers in Arab Countries, 2022-2050.Oman medical journal · 2026Article
- Impact of body mass index on dietary habits and health behaviors in breast cancer patients.Frontiers in oncology · 2026Article
- Effects of acute exercise on inflammatory and metabolic biomarkers in women: a randomized controlled trial.NPJ breast cancer · 2025Article
- Observational
- Article
- Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.BMC cancer · 2025Article
- Mammographic calcifications association with risk of advanced breast cancer.Breast cancer research and treatment · 2025Article
- Weight Loss Reverses the Effects of Aging and Obesity on Mammary Tumor Immunosuppression and Progression.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Association between daily sitting time and breast cancer among obese women: a nationwide population-based study.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
contextBreast cancer is increasing in prevalence in parallel with rising rates of obesity worldwide. Obesity is recognized as a leading modifiable risk factor for the development of breast cancer; however, this association varies considerably by clinicopathologic features, and the underlying mechanisms are complex. EVIDENCE ACQUISITION: Pubmed literature search using combinations of "obesity," "breast cancer risk," "diet," "exercise," "weight gain," "weight loss," "adipose tissue inflammation," "crown-like structure," "immune markers," "metformin," "gliflozins," "SGLT-2i," "GLP1-RA," and related terms. EVIDENCE SYNTHESIS: Elevated body mass index and weight gain are associated with increased risk of postmenopausal, hormone receptor-positive breast cancer. Emerging evidence suggests that adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk. Mechanistically, various factors including altered adipokine balance, dysfunctional adipose tissue, dysregulated insulin signaling, and chronic inflammation contribute to tumorigenesis. Weight loss and more specifically fat mass loss through lifestyle and pharmacologic interventions improve serum metabolic and inflammatory markers, sex hormone levels, and measures of breast density, suggesting a link to decreased breast cancer risk.
conclusionIncorporating markers of metabolic health and body composition measures with body mass index can capture breast cancer risk more comprehensively. Further studies of interventions targeting body fat levels are needed to curb the growing prevalence of obesity-related cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.